Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab in MMR Deficient or POLE Mutated Metastatic Colorectal Cancer
NCT03435107Phase 2Completed
- Sponsor
- Asan Medical Center
- Start
- Apr 2018
- Primary completion
- Apr 2023
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of durvalumab in metastatic colorectal cancer (mCRC), sponsored by Asan Medical Center. Started Apr 2018; status: completed.
02
Drugs
durvalumab
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT03435107.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03435107.